专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004035615A3 FACTOR INVOLVED IN METASTASIS AND USES THEREOF 审中-公开
标题翻译：涉及转移因子的因子及其用途
公开(公告)号：WO2004035615A3
公开(公告)日：2004-06-03
申请号：PCT/EP0311604
申请日：2003-10-20
申请人： ATUGEN AG , KLIPPEL-GIESE ANKE , KAUFMANN JOERG , SCHWARZER ROLF
发明人： KLIPPEL-GIESE ANKE , KAUFMANN JOERG , SCHWARZER ROLF
IPC分类号： A61K38/00 , A61P35/00 , C07K14/00 , C07K14/47 , C12N15/12 , C07K16/18 , C12N15/11 , G01N33/50 , C04K14/47
CPC分类号： C07K14/4747 , A61K38/00 , C07K14/4702
摘要： The present invention is related to a nucleic acid coding for a factor involved in a biological process, whereby the process is a PI 3-kinase pathway regulated process, preferably a process selected from the group comprising glucose metabolism, amino acid and glucose deprivation processes, diabetes, wound healing, stress response, apoptosis, metastasis, tumorigenesis, cell migration, cell motility in extracellular matrix and cell growth in extracellular matrix, and the factor is a polypeptide comprising an amino acid sequence according to SEQ ID. NO. 1 or a polypeptide having a sequence according to databank entries gi 9506687 or NP_061931, preferably NP_061931.1.
摘要翻译：本发明涉及编码参与生物过程的因子的核酸，其中该过程是PI3-激酶途径调控过程，优选选自葡萄糖代谢，氨基酸和葡萄糖剥夺过程的过程，糖尿病，创伤愈合，应激反应，细胞凋亡，转移，肿瘤发生，细胞迁移，细胞外基质中的细胞运动和细胞外基质中的细胞生长，所述因子是包含根据SEQ ID.NO.1的氨基酸序列的多肽。没有。 1或具有根据数据库条目gi 9506687或NP_061931，优选NP_061931.1的序列的多肽。

2. 发明申请

WO2008009477A3 MEANS FOR INHIBITING THE EXPRESSION OF PROTEIN KINASE 3 审中-公开
标题翻译：抑制蛋白激酶3表达的手段
公开(公告)号：WO2008009477A3
公开(公告)日：2008-05-29
申请号：PCT/EP2007006492
申请日：2007-07-20
申请人： SILENCE THERAPEUTICS AG , KAUFMANN JOERG , KEIL OLIVER , SANTEL ANSGAR
发明人： KAUFMANN JOERG , KEIL OLIVER , SANTEL ANSGAR
IPC分类号： C12N9/12 , C12N15/113
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/321 , C12N2310/3521
摘要： The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least partially complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ.ID.No. 1 (NM_013355), or part thereof whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 482 to 500 of SEQ. ID.No. 1 (SEQ. ID.No. 2); from nucleotide positions 1555 to 1573 of SEQ. ID.No. 1 (SEQ.ID.No. 4); from nucleotide positions 1556 to 1574 of SEQ. ID.No. 1 (SEQ.ID.No. 6); from nucleotide positions 1559 to 1577 of SEQ. ID.No. 1 (SEQ.ID.No. 8); from nucleotide positions 1566 to 1584 of SEQ. ID.No. 1 (SEQ.ID.No. 10); from nucleotide positions 2094 to 2112 of SEQ. ID.No. 1 (SEQ.ID.No. 12); from nucleotide positions 2102 to 2120 of SEQ. ID.No. 1 (SEQ.ID.No. 14); from nucleotide positions 2286 to 2304 of SEQ. ID.No. 1 (SEQ.ID.No. 16); from nucleotide positions 2761 to 2779 of SEQ. ID.No. 1 (SEQ.ID.No. 18); from nucleotide positions 2763 to 2781 of SEQ. ID.No. 1 (SEQ.ID.No. 20); from nucleotide positions 2764 to 2782 of SEQ. ID.No. 1 (SEQ.ID.No. 22); from nucleotide positions 2843 to 2861 of SEQ. ID.No. 1 (SEQ.ID.No. 24); from nucleotide positions 2844 to 2862 of SEQ. ID.No. 1 (SEQ.ID.No. 26); or from nucleotide positions 2846 to 2864 of SEQ. ID.No. 1 (SEQ.ID.No. 28), preferably the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1555 to 1573 of SEQ. ID.No. 1 (SEQ.ID.No. 4); from nucleotide positions 1556 to 1574 of SEQ. ID.No. 1 (SEQ.ID.No. 6); from nucleotide positions 1559 to 1577 of SEQ. ID.No. 1 (SEQ.ID.No. 8); from nucleotide positions 1566 to 1584 of SEQ. ID.No. 1 (SEQ.ID.No. 10); from nucleotide positions 2094 to 2112 of SEQ. ID.No. 1 (SEQ.ID.No. 12); or from nucleotide positions 2286 to 2304 of SEQ. ID.No. 1 (SEQ.ID.No. 16), whereby preferably the first stretch is additionally at least partially complementary to a region preceding the 5' end of the nucleotide core sequence and/or to a region following the 3' end of the nucleotide core sequence.
摘要翻译：本发明涉及包含双链结构的核酸分子，其中双链结构包含第一链和第二链，其中第一链包含第一段连续核苷酸，并且所述第一段至少为与靶核酸部分互补，并且其中第二链包含第二段连续核苷酸，并且所述第二段与第一段至少部分互补，由此第一段包含至少部分与第一段互补的核酸序列根据SEQ.ID.No.的核酸序列的核苷酸核心序列。 1（NM_013355）或其部分，其中所述核苷酸核心序列包含SEQ.ID.NO.1的核苷酸位置482至500的核苷酸序列。证件号码。 1（SEQ.ID.No.2）; 从SEQ.ID.No.1的核苷酸位置1555至1573。证件号码。 1（SEQ.ID.No.4）; 从SEQ.ID.No.1的核苷酸位置1556至1574。证件号码。 1（SEQ.ID.No.6）; 从SEQ.ID.No.1的核苷酸位置1559至1577。证件号码。 1（SEQ.ID.No.8）; 从SEQ.ID.NO.1的核苷酸位置1566至1584。证件号码。 1（SEQ.ID.No.10）; 从SEQ.ID.No.1的核苷酸位置2094至2112。证件号码。 1（SEQ.ID.No.12）; 从SEQ.ID.No.1的核苷酸位置2102至2120。证件号码。 1（SEQ.ID.No.14）; 从SEQ.ID.No.1的核苷酸位置2286至2304。证件号码。 1（SEQ.ID.No.16）; 从SEQ.ID.No.1的核苷酸位置2761至2779。证件号码。 1（SEQ.ID.No.18）; 从SEQ.ID.No.1的核苷酸位置2763至2781。证件号码。 1（SEQ.ID.No.20）; 从SEQ.ID.No.1的核苷酸位置2764至2782。证件号码。 1（SEQ.ID.No.22）; 从SEQ.ID.No.2843至2861的核苷酸位置开始。证件号码。 1（SEQ.ID.No.24）; 从SEQ.ID.No.2844至2862的核苷酸位置开始。证件号码。 1（SEQ.ID.No.26）; 或从SEQ.ID.No.2846至2864的核苷酸位置。证件号码。 1（SEQ.ID.No.28），优选核苷酸核心序列包含SEQ.ID.No.2的核苷酸位置1555至1573的核苷酸序列。证件号码。 1（SEQ.ID.No.4）; 从SEQ.ID.No.1的核苷酸位置1556至1574。证件号码。 1（SEQ.ID.No.6）; 从SEQ.ID.No.1的核苷酸位置1559至1577。证件号码。 1（SEQ.ID.No.8）; 从SEQ.ID.NO.1的核苷酸位置1566至1584。证件号码。 1（SEQ.ID.No.10）; 从SEQ.ID.No.1的核苷酸位置2094至2112。证件号码。 1（SEQ.ID.No.12）; 或从SEQ.ID.No.1的核苷酸位置2286至2304。证件号码。 1（SEQ.ID.No. 16），其中优选第一段另外至少部分地与核苷酸核心序列的5'末端之前的区域和/或核苷酸核心的3'末端之后的区域互补序列。

3. 发明申请

WO2005105152A3 LIPIDS, LIPID COMPLEXES AND USE THEREOF 审中-公开
标题翻译：脂肪酸，脂质复合物及其用途
公开(公告)号：WO2005105152A3
公开(公告)日：2006-09-14
申请号：PCT/EP2005004920
申请日：2005-05-06
申请人： ATUGEN AG , KEIL OLIVER , KAUFMANN JOERG
发明人： KEIL OLIVER , KAUFMANN JOERG
IPC分类号： A61K47/48 , C07C237/06 , C07C237/22 , C07C279/14 , C12N15/11 , C12N15/113
CPC分类号： C07C209/50 , A61K9/1271 , A61K9/1272 , A61K31/713 , A61K47/183 , A61K47/186 , A61K47/24 , A61K47/543 , A61K47/544 , A61K47/6911 , C07C231/02 , C07C279/14 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/14 , C12N2310/321 , C12N2320/32 , C12N2310/3521
摘要： The present invention is related to a compound according to formula (I), wherein R 1 and R 2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R 3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and YÉ is a pharmaceutically acceptable anion.
摘要翻译：本发明涉及式（I）化合物，其中R 1和R 2各自独立地选自烷基; n是1到4之间的整数; R 3是选自根据式（II）的赖氨酰，鸟氨酰基，2,4-二氨基丁酰基，组氨酰和酰基部分的酰基，其中m是1至3的整数，YÉ 是药学上可接受的阴离子。

4. 发明申请

WO2006069782A2 COATED LIPID COMPLEXES AND THEIR USE 审中-公开
标题翻译：涂层脂肪复合物及其用途
公开(公告)号：WO2006069782A2
公开(公告)日：2006-07-06
申请号：PCT/EP2005014074
申请日：2005-12-27
申请人： ATUGEN AG , KEIL OLIVER , KAUFMANN JOERG
发明人： KEIL OLIVER , KAUFMANN JOERG
IPC分类号： A61K47/48
CPC分类号： A61K47/48815 , A61K31/713 , A61K47/543 , A61K47/6911 , A61K48/0033 , Y10S977/907 , Y10T428/2984
摘要： The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.
摘要翻译：本发明涉及包含至少第一种脂质组分，至少第一辅助脂质和在体内条件下可从脂质组合物中除去的屏蔽化合物的脂质组合物。

5. 发明申请

WO2006069782A3 LIPID COMPLEXES COATED WITH PEG AND THEIR USE 审中-公开
标题翻译：用PEG涂覆的脂肪复合物及其用途
公开(公告)号：WO2006069782A3
公开(公告)日：2007-04-12
申请号：PCT/EP2005014074
申请日：2005-12-27
申请人： ATUGEN AG , KEIL OLIVER , KAUFMANN JOERG
发明人： KEIL OLIVER , KAUFMANN JOERG
IPC分类号： A61K47/48
CPC分类号： A61K47/48815 , A61K31/713 , A61K47/543 , A61K47/6911 , A61K48/0033 , Y10S977/907 , Y10T428/2984
摘要： The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.
摘要翻译：本发明涉及包含至少第一种脂质组分，至少第一辅助脂质和在体内条件下可从脂质组合物中除去的屏蔽化合物的脂质组合物。

6. 发明申请

WO2010091878A3 MEANS FOR INHIBITING THE EXPRESSION OF OPA1 审中-公开
标题翻译：用于抑制OPA1表达的手段
公开(公告)号：WO2010091878A3
公开(公告)日：2010-11-25
申请号：PCT/EP2010000888
申请日：2010-02-12
申请人： SILENCE THERAPEUTICS AG , KAUFMANN JOERG , SANTEL ANSGAR
发明人： KAUFMANN JOERG , SANTEL ANSGAR
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N2310/14
摘要： The present invention is related to an siRNA comprising an antisense strand and a sense strand, wherein all or a portion of said antisense strand comprises an antisense duplex region, wherein all or a portion of said sense strand comprises a sense duplex region, wherein said antisense duplex region is at least partially complementary to said sense duplex region, wherein said siRNA comprises a duplex region consisting of said antisense duplex region and said sense duplex region, and wherein: a) said antisense strand comprises SEQ ID NO: 3, 5, 7 or 9; or b) said antisense strand comprises an antisense duplex region, all or a portion of which, is complementary to a portion of SEQ ID NOs: 1, 10, 11, 12, 13, 14, 15 and/or 16.
摘要翻译：本发明涉及包含反义链和有义链的siRNA，其中所述反义链的全部或一部分包含反义双链体区，其中所述有义链的全部或一部分包含有义双链体区，其中所述反义链其中所述siRNA包含由所述反义双链体区和所述有义双链体区组成的双链体区，并且其中：a）所述反义链包含SEQ ID NO：3,5,7 或9; 或b）所述反义链包含反义双链体区，其全部或部分与SEQ ID NO：1,10,11,12,13,14,15和/或16的一部分互补。

7. 发明申请

WO2010034487A3 MEANS FOR INHIBITING THE EXPRESSION OF ORC-1 审中-公开
标题翻译：抑制ORC-1表达的手段
公开(公告)号：WO2010034487A3
公开(公告)日：2010-05-20
申请号：PCT/EP2009006889
申请日：2009-09-23
申请人： SILENCE THERAPEUTICS AG , GOSSEN MANFRED , SANTEL ANSGAR , KAUFMANN JOERG
发明人： GOSSEN MANFRED , SANTEL ANSGAR , KAUFMANN JOERG
IPC分类号： C12N15/113
CPC分类号： C12N15/1135 , C12N15/113 , C12N2310/14
摘要： The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ. ID.No. 1, whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1755 to 1763 of SEQ. ID.No 1; from nucleotide positions 1904 to 1912 of SEQ.ID.No.l; from nucleotide positions 1905 to 1913 of SEQ.ID.No.l; from nucleotide positions 2548 to 2556 of SEQ.ID.No.l whereby the first stretch is additionally at least partially complementary to a region preceding the 5' end of the nucleotide core sequence and/or to a region following the 3' end of the nucleotide core sequence.
摘要翻译：本发明涉及包含双链结构的核酸分子，其中双链结构包含第一链和第二链，其中第一链包含第一段连续核苷酸，并且所述第一段至少为与靶核酸部分互补，并且其中第二链包含第二段连续核苷酸，并且所述第二段与第一段至少部分互补，由此第一段包含至少与第二段互补的核酸序列根据SEQ.ID.NO.1的核酸序列的核苷酸核心序列。证件号码。 1，其中所述核苷酸核心序列包含SEQ.ID.NO.1的核苷酸位置1755至1763的核苷酸序列。 ID.No 1; 从SEQ.ID.No.1的核苷酸位置1904至1912; 从SEQ.ID.No.1的核苷酸位置1905至1913; 从SEQ.ID.No.1的核苷酸位置2548至2556，其中第一段另外至少部分地与核苷酸核心序列的5'末端之前的区域和/或跟随该序列的3'末端之后的区域互补核苷酸核心序列。

8. 发明申请

WO2007121946A3 MEANS FOR INHIBITING THE EXPRESSION OF CD31 审中-公开
标题翻译：意思是抑制CD31的表达
公开(公告)号：WO2007121946A3
公开(公告)日：2008-01-10
申请号：PCT/EP2007003495
申请日：2007-04-20
申请人： SILENCE THERAPEUTICS AG , KAUFMANN JOERG , KEIL OLIVER , SANTEL ANSGAR
发明人： KAUFMANN JOERG , KEIL OLIVER , SANTEL ANSGAR
IPC分类号： C12N15/113
CPC分类号： C12N15/1138 , C12N2310/14
摘要： The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ. ID.No. 1, whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1277 to 1295 of SEQ. ID.No 1; from nucleotide positions 2140 to 2158 of SEQ.ID.No.l; from nucleotide positions 2391 to 2409 of SEQ.ID.No.l; and whereby the first stretch is additionally at least partially complementary to a region preceding the 5' end of the nucleotide core sequence and/or to a region following the 3' end of the nucleotide core sequence.
摘要翻译：本发明涉及包含双链结构的核酸分子，由此双链结构包含第一链和第二链，其中第一链包含连续核苷酸的第一段，并且所述第一段至少是与靶核酸部分互补，并且其中所述第二链包含连续核苷酸的第二段，所述第二段与所述第一段至少部分互补，由此所述第一段包含与至少互补的核酸序列根据SEQ.ID.NO.1的核酸序列的核苷酸核心序列。证件号码。 1，其中核苷酸核心序列包含SEQ ID NO：1的核苷酸位置1277至1295。 ID.No 1; SEQ ID NO：1的核苷酸位置2140至2158; SEQ ID NO：1的核苷酸位置2391至2409; 并且其中第一段延伸另外至少部分地与核苷酸核心序列的5'末端之前的区域和/或与核苷酸核心序列的3'末端之后的区域互补。

9. 发明申请

WO2005000320A2 USE OF DOUBLE-STRANDED RIBONUCLEIC ACID FOR INDUCING CELL LYSIS 审中-公开
标题翻译：双链核糖核酸在诱导细胞裂解中的应用
公开(公告)号：WO2005000320A2
公开(公告)日：2005-01-06
申请号：PCT/EP2004006999
申请日：2004-06-28
申请人： ATUGEN AG , GIESE KLAUS , KAUFMANN JOERG
发明人： GIESE KLAUS , KAUFMANN JOERG
IPC分类号： A61K31/713 , A61P35/00 , C12N15/11 , C12N15/113
CPC分类号： A61K31/713 , C12N15/11 , C12N15/1137 , C12N2310/14 , C12N2310/317 , C12N2310/332 , C12N2310/346 , C12N2310/53 , C12Y301/03048
摘要： The present invention is related to the use of a ribonucleic acid for the manufacture of a medicament, whereby the ribonucleic acid comprises a double-stranded structure and the double-stranded structure comprises a first and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and the second strand comprises a second stretch of contiguous nucleotides, whereby the first stretch is not complementary to a nucleic acid, preferably a mRNA, of a cell of an organism to be treated with said medicament and/or whereby the second stretch is different from a nucleic acid, preferably a mRNA of a cell of an organism to be treated with said medicament.
摘要翻译：本发明涉及核糖核酸用于制造药物的用途，其中所述核糖核酸包含双链结构并且所述双链结构包含第一链和第二链，其中所述第一链包含第一链一段连续的核苷酸，并且第二链包含第二段连续的核苷酸，由此第一段与待用所述药剂处理的生物细胞的核酸，优选mRNA互补，和/或第二段拉伸不同于核酸，优选待用所述药物治疗的生物细胞的mRNA。

10. 发明申请

WO2004015107A3 FURTHER NOVEL FORMS OF INTERFERING RNA MOLECULES 审中-公开
标题翻译：干扰RNA分子的进一步的新形式
公开(公告)号：WO2004015107A3
公开(公告)日：2004-04-29
申请号：PCT/EP0308666
申请日：2003-08-05
申请人： ATUGEN AG , GIESE KLAUS , KAUFMANN JOERG , KLIPPEL-GIESE ANKE
发明人： GIESE KLAUS , KAUFMANN JOERG , KLIPPEL-GIESE ANKE
IPC分类号： A01K67/027 , A61K31/713 , A61K38/00 , C07H21/00 , C12N5/10 , C12N15/11 , C12Q1/68
CPC分类号： C12N15/1137 , A61K31/713 , A61K38/00 , C12N5/10 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/3183 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/343 , C12N2310/346 , C12N2310/3521 , C12N2310/3525 , C12N2310/53 , C12N2310/531 , C12N2320/51 , C12Q1/68 , C12Y207/11001
摘要： The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double- stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
摘要翻译：本发明涉及包含双链结构的核糖核酸，由此双链结构包含第一链和第二链，其中第一链包含连续核苷酸的第一段，其中所述第一段至少部分互补并且第二链包含连续核苷酸的第二段，其中所述第二段与靶核酸至少部分相同，由此双链结构是平端的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式